FDA to evaluate Avastin for deadly form of brain cancer

03/10/2009 | Forbes

An FDA panel is scheduled March 31 to review Genentech's application to promote Avastin as a treatment for a deadly form of brain cancer called glioblastoma multiforme. Avastin, which is approved to treat colon, breast and lung cancers, generated $2.69 billion in U.S. sales last year.

View Full Article in:

Forbes

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
Genentech
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX